Consensus LENZ Therapeutics, Inc.

Equities

LENZ

US52635N1037

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
15.72 ^USD	-1.19%		-4.32%	0.00%

Apr. 15	Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target	MT
Apr. 15	William Blair Starts LENZ Therapeutics With Outperform Rating	MT

Evolution of the average Target Price on LENZ Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

50adbaa53cd35d.LW8mYM3UFCoAiwp3UDihRlTtKUXBVFAYrD9XLqO8Mls.fSlAC4DkdXhEyUwECXOZFhanXRGrEiIt1U8mStX-eGkYGX4lqrJuRlPfaQ~64949bb868282b34584861c69ba4e0eb

Analyst Recommendations on LENZ Therapeutics, Inc.

Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target	Apr. 15	MT
William Blair Starts LENZ Therapeutics With Outperform Rating	Apr. 15	MT
Piper Sandler Initiates LENZ Therapeutics at Overweight With $28 Price Target	Mar. 27	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.72 USD

Average target price

36.75 USD

Spread / Average Target

+133.78%

High Price Target

45 USD

Spread / Highest target

+186.26%

Low Price Target

32 USD

Spread / Lowest Target

+103.56%

Consensus detail

Consensus revision (last 18 months)

Analysts covering LENZ Therapeutics, Inc.

Leerink Partners
William Blair & Co.
Piper Sandler

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar